NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $0.35 -0.01 (-2.77%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.3750-Day Range$0.34▼$0.6252-Week Range$0.13▼$1.90Volume141,559 shsAverage Volume824,626 shsMarket Capitalization$24.64 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Brainstorm Cell Therapeutics alerts: Email Address Brainstorm Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside468.8% Upside$2.00 Price TargetShort InterestHealthy1.54% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.60Based on 7 Articles This WeekInsider TradingSelling Shares$22,050 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector183rd out of 936 stocksBiological Products, Except Diagnostic Industry21st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBrainstorm Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Brainstorm Cell Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.54% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently decreased by 26.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBrainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Brainstorm Cell Therapeutics is -0.66. Previous Next 2.0 News and Social Media Coverage News SentimentBrainstorm Cell Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Brainstorm Cell Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,050.00 in company stock.Percentage Held by InsidersOnly 5.45% of the stock of Brainstorm Cell Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.Read more about Brainstorm Cell Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Brainstorm Cell Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Read More BCLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCLI Stock News HeadlinesJuly 25 at 6:36 AM | insidertrades.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insider Sells 63,000 SharesJuly 26 at 7:38 AM | americanbankingnews.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insider Ibrahim B. Dagher Sells 63,000 SharesJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 24 at 8:30 AM | prnewswire.comBCLI Update - Progress Supports Our 10x Plus Value Range PotentialJuly 22, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.comJuly 1, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn ProgramJune 27, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct OfferingJune 26, 2024 | prnewswire.comBrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical TrialJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 20, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating OfficerJune 14, 2024 | prnewswire.comBCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness ExpectationMay 20, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwnMay 16, 2024 | msn.comBrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02May 15, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateApril 17, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 17, 2024 | msn.comBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical OfficerApril 17, 2024 | msn.comBrainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55See More Headlines Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCLI CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+468.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-431.16% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-4.40Miscellaneous Outstanding Shares70,080,000Free Float66,262,000Market Cap$24.64 million OptionableOptionable Beta0.37 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Chaim Lebovits (Age 53)President & Co-CEO Comp: $878.78kDr. Irit Arbel DSc (Age 64)Ph.D., Co-Founder & Independent Vice Chair of the Board Ms. Alla Patlis CPA (Age 37)M.B.A., Interim CFO & Controller Comp: $130.92kMr. Uri Yablonka (Age 47)Executive VP, Chief Business Officer, Secretary & Director Comp: $247.06kDr. Daniel Offen Ph.D.Chief Scientific AdvisorMs. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government AffairsDr. Ibrahim Dagher M.D. (Age 55)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsChampions OncologyNASDAQ:CSBRDBV TechnologiesNASDAQ:DBVTAtlantic Coastal Acquisition Corp. IINASDAQ:ACABAlloVirNASDAQ:ALVRCASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInsidersIbrahim B. DagherSold 63,000 sharesTotal: $22,050.00 ($0.35/share)Stacy LindborgBought 11,500 shares on 9/1/2023Total: $20,355.00 ($1.77/share)View All Insider Transactions BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI shares have increased by 28.8% and is now trading at $0.3516. View the best growth stocks for 2024 here. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX). This page (NASDAQ:BCLI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts